ArticleAIDS research and therapy2025
Prevalence and risk factors of adverse drug events with dolutegravir-based regimens among Thai people living with HIV: a retrospective cohort study.
Article in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preparation, Oral SNEDDS Formulation, and In Vivo Evaluation of the HIV-1 Latency-Reversing Agent EK-16A.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDolutegravir (DTG)-based antiretroviral therapy (ART) is a preferred first-line treatment for HIV/AIDS, but concerns about adverse drug events (ADEs) persist. This study aimed to determine the prevalence of ADEs and identify associated independent risk factors among Thai people living with HIV (PLWH) on DTG-based regimens for at least one year.
methodsThis retrospective cohort study examined 1,270 Thai individuals living with HIV receiving a DTG/3TC/TDF regimen for ≥ 1 year at a secondary care hospital between 2021 and 2023. The primary outcome was any ADE (Grade ≥ 1) documented during the first 12 months of DTG therapy. Multivariate logistic regression, adjusted for confounders including sex, was used to identify independent predictors of ADEs.
resultsAmong 1,270 participants, 684 (53.86%) experienced at least one ADE. The cohort was predominantly ART-experienced, with a median duration since HIV diagnosis of 6.00 years (IQR 4.00-9.00 years). The most frequent ADEs included a decline in estimated glomerular filtration rate (eGFR) (17.72%), anemia (15.43%), weight gain (9.29%), and nausea (7.80%). Independent risk factors associated with increased ADE odds were: older age (≥ 40 years vs. 18-29 years, global p = 0.040), psychiatric comorbidity (aOR 3.13; 95% CI 1.02-9.56; p = 0.046), history of cryptococcosis (aOR 1.45; 95% CI 1.05-2.13; p = 0.035) ,underweight status (BMI < 18.5 kg/m²) (aOR 2.22; 95% CI 1.50-3.38; p < 0.001), and baseline eGFR < 90 mL/min/1.73m
conclusionsOver half (53.86%) of patients on long-term DTG-based therapy experienced at least one ADE. Risk was significantly elevated in older adults, those with psychiatric illness, previous cryptococcosis, underweight status, or lower baseline eGFR. Healthcare providers should implement proactive monitoring and tailored management strategies for these high-risk patients to optimize ART safety and efficacy outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.